Industry
Medical - Devices
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Loading...
Open
1.06
Mkt cap
12M
Volume
58K
High
1.12
P/E Ratio
-0.14
52-wk high
4.88
Low
1.04
Div yield
N/A
52-wk low
0.60
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 11:55 am
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 11:56 am
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 9:31 am
Portfolio Pulse from Benzinga Newsdesk
September 03, 2024 | 11:57 am
Portfolio Pulse from Benzinga Newsdesk
August 20, 2024 | 12:18 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 12:55 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 12:28 pm
Portfolio Pulse from Benzinga Insights
June 17, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
June 13, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
June 13, 2024 | 12:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.